In accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB’s (”Vivesto”) Annual General Meeting in 2025, it is hereby announced that the Nomination Committee for the Annual General Meeting 2027 has been appointed, based on the ownership structure as per 30 September 2026.
The Nomination Committee for the Annual General Meeting 2027 comprises the following members:
Per Arwidsson has been appointed Chairman of the Nomination Committee.
Vivesto’s Annual General Meeting will be held on 13 May 2027 in Stockholm.
Shareholders who wish to submit proposals to the Nomination Committee for the Annual General Meeting 2027 may send them by e-mail to nomination@vivesto.com. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted no later than 31 January 2027.
For further information, please contact:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.